252 related articles for article (PubMed ID: 27770561)
41. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
[TBL] [Abstract][Full Text] [Related]
42. Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.
Macías J; Téllez F; de Los Santos I; Morano LE; Merino D; Granados R; Vera-Mendez F; González-Serna A; Campo-Moneo E; García-Fraile L; García F; Real LM; Pineda JA;
J Viral Hepat; 2021 Jun; 28(6):878-886. PubMed ID: 33721377
[TBL] [Abstract][Full Text] [Related]
43. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.
Serfaty L; Jacobson I; Rockstroh J; Altice FL; Hwang P; Barr E; Robertson M; Haber B
J Viral Hepat; 2019 Mar; 26(3):329-336. PubMed ID: 30412325
[TBL] [Abstract][Full Text] [Related]
44. The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial.
AlEid A; Al Balkhi A; Qutub A; Abbarh S; AlLehibi A; Almtawa A; Al Otaibi N; AlGhamdi A; AlGhamdi A; Alamr A; Ahmad S; Al Sayari K; Al Ibrahim B; AlKhathlan A
Saudi J Gastroenterol; 2022; 28(3):225-232. PubMed ID: 35142658
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S1-S8. PubMed ID: 32539296
[TBL] [Abstract][Full Text] [Related]
46. Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done.
Llerena S; Cabezas J; Cuadrado A; Manuel Olmos J; González M; García F; Cobo C; Crespo J
Ann Hepatol; 2019; 18(1):236-239. PubMed ID: 31113598
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis.
Chayanupatkul M; Chittmittraprap S; Pratedrat P; Chuaypen N; Avihingsanon A; Tangkijvanich P
Antivir Ther; 2020; 25(6):305-314. PubMed ID: 32910788
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
[TBL] [Abstract][Full Text] [Related]
49. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
[TBL] [Abstract][Full Text] [Related]
50. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
[TBL] [Abstract][Full Text] [Related]
51. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.
Liu CH; Peng CY; Fang YJ; Kao WY; Yang SS; Lin CK; Lai HC; Su WP; Fang SU; Chang CC; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
Sci Rep; 2020 Jun; 10(1):9180. PubMed ID: 32513953
[TBL] [Abstract][Full Text] [Related]
52. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Durand CM; Bowring MG; Brown DM; Chattergoon MA; Massaccesi G; Bair N; Wesson R; Reyad A; Naqvi FF; Ostrander D; Sugarman J; Segev DL; Sulkowski M; Desai NM
Ann Intern Med; 2018 Apr; 168(8):533-540. PubMed ID: 29507971
[TBL] [Abstract][Full Text] [Related]
53. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
Kramer JR; Puenpatom A; Erickson KF; Cao Y; Smith D; El-Serag HB; Kanwal F
J Viral Hepat; 2018 Nov; 25(11):1270-1279. PubMed ID: 29851265
[TBL] [Abstract][Full Text] [Related]
54. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
Zamor PJ; Vierling J; Ghalib R; Luketic V; Ravendhran N; Balart L; Robertson M; Hwang P; Hanna GJ; Nguyen BY; Barr E; Talwani R; Pearlman B
Am J Gastroenterol; 2018 Jun; 113(6):863-871. PubMed ID: 29695828
[TBL] [Abstract][Full Text] [Related]
55. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
Wei L; Kumada H; Perumalswami PV; Tanwandee T; Cheng W; Heo J; Cheng PN; Hwang P; Mu SM; Zhao XM; Asante-Appiah E; Caro L; Hanna GJ; Robertson MN; Haber BA; Talwani R
J Gastroenterol Hepatol; 2019 Sep; 34(9):1597-1603. PubMed ID: 30779220
[TBL] [Abstract][Full Text] [Related]
56. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
Liu J; Guo M; Ke L; You R
Front Public Health; 2022; 10():836986. PubMed ID: 35646774
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
Choi DT; Puenpatom A; Yu X; Erickson KF; Kanwal F; El-Serag HB; Kramer JR
Antiviral Res; 2020 Feb; 174():104698. PubMed ID: 31862503
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis.
Asselah T; Zeuzem S; Reau N; Hwang P; Long J; Talwani R; Robertson MN; Haber BA
Curr Med Res Opin; 2020 Aug; 36(8):1325-1332. PubMed ID: 32459122
[No Abstract] [Full Text] [Related]
59. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
Foster GR; Pianko S; Brown A; Forton D; Nahass RG; George J; Barnes E; Brainard DM; Massetto B; Lin M; Han B; McHutchison JG; Subramanian GM; Cooper C; Agarwal K;
Gastroenterology; 2015 Nov; 149(6):1462-70. PubMed ID: 26248087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
